胱抑素C证实卡格列净对eGFR斜率获益:CANPIONE研究
CANPIONE研究预设探索性分析显示,在2型糖尿病伴微量白蛋白尿患者中,卡格列净组慢性eGFR-胱抑素C斜率为-0.4,对照组为-4.9 ml/min/1.73 m²/年,组间差异4.4(95%CI 1.3-7.6)。eGFR-肌酐斜率组间差异3.5(95%CI 0.2-6.8),方向一致,支持肌酐斜率分析的临床可靠性。
要点
- 卡格列净减缓胱抑素C估算的eGFR慢性下降斜率。
- 胱抑素C与肌酐两种标志物评估的eGFR轨迹方向一致。
- 体重、BMI、腰围变化与eGFR-胱抑素C变化相关性弱。
核心结论
- 基于胱抑素C的eGFR斜率分析支持既往肌酐斜率结果的稳健性。
- 在SGLT2抑制剂治疗患者中,eGFR-肌酐斜率分析保留合理的临床可靠性。
研究设计与样本
- CANPIONE研究为在日本2型糖尿病伴微量白蛋白尿患者中开展的预干预斜率设计研究。
- 本文为预设探索性分析,采用双斜率线性样条混合效应模型评估慢性eGFR-胱抑素C和eGFR-肌酐斜率。
- 使用Pearson相关系数评估eGFR变化与体成分相关参数变化之间的关联。
主要发现
- 卡格列净组慢性eGFR-胱抑素C斜率为-0.4(95%CI -2.6至1.8)ml/min/1.73 m²/年,对照组为-4.9(95%CI -7.1至-2.6)ml/min/1.73 m²/年。
- 慢性eGFR-胱抑素C斜率的组间差异为4.4(95%CI 1.3-7.6)ml/min/1.73 m²/年。
- 同一时间点计算的eGFR-肌酐慢性斜率组间差异为3.5(95%CI 0.2-6.8)ml/min/1.73 m²/年。
- 卡格列净降低体重、BMI和腰围,但这些变化与eGFR-胱抑素C变化之间相关性弱。
临床怎么用
- 对于接受SGLT2抑制剂治疗的2型糖尿病伴微量白蛋白尿患者,eGFR-肌酐斜率仍可作为临床评估肾功能下降的可靠指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In the canagliflozin in type 2 diabetic patients with microalbuminuria in Japanese population (CANPIONE) study with a novel preintervention slope design, canagliflozin attenuated the decline in creatinine-based estimated glomerular filtration rate (eGFR-creatinine) slope in patients with type 2 diabetes mellitus and microalbuminuria. However, because serum creatinine is affected by muscle mass, the reliability of the eGFR-creatinine slope may be limited. Therefore, this prespecified exploratory analysis aimed to evaluate the effect of canagliflozin on the cystatin C-based eGFR (eGFR-cystatin C) slope, which is less affected by muscle mass, to validate the robustness of the previous findings. METHODS: The chronic eGFR-cystatin C and eGFR-creatinine slopes were assessed using a 2-slope linear spline mixed-effects model. Pearson correlation coefficients were used to evaluate associations between changes in eGFR and body composition-related parameters. RESULTS: eGFR trajectories were directionally consistent across both filtration markers. The chronic eGFR-cystatin C slopes in the canagliflozin and control groups were -0.4 (95% confidence interval [CI], -2.6 to 1.8) and -4.9 (-7.1 to -2.6) ml/min per 1.73 m2/year, respectively, corresponding to a between-group difference of 4.4 (1.3-7.6) ml/min per 1.73 m2/year. Similar trends were observed in the eGFR-creatinine slopes derived from the same time points, yielding a comparable treatment effect on the chronic slope (between-group difference: 3.5 [0.2-6.8] ml/min per 1.73 m2/year). Canagliflozin reduced body weight, body mass index (BMI), and waist circumference, whereas little correlation was observed between these changes and changes in eGFR-cystatin C. CONCLUSION: Incorporating the eGFR-cystatin C slope analysis supports the robustness of the previous creatinine-based slope findings, suggesting that the eGFR-creatinine slope analysis retains reasonable clinical reliability in patients treated with sodium-glucose cotransporter 2 inhibitors (SGLT2is).
引用
- Miyamoto S, Heerspink HJL, de Zeeuw D, et al. Cystatin C Confirms the Canagliflozin eGFR Slope Benefit in CANPIONE. Kidney Int Rep. 2026. PMID: 41907819. doi:10.1016/j.ekir.2026.106374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。